Literature DB >> 20367791

Clinical, epidemiological characteristics and indications for liver biopsy and treatment in immigrants with chronic hepatitis B at a referral hospital in Madrid.

J A Pérez-Molina1, J M Herrero-Martínez, F Norman, A Pérez-Ayala, B Monge-Mahillo, M Navarro-Beltrá, R López-Vélez.   

Abstract

The increase in immigration from less developed countries to Europe has led to an increase in the incidence of hepatitis B infection. The objective of this study was to describe the clinical, epidemiological characteristics and indications for treatment of chronic hepatitis B in a cohort of immigrants, given the relative lack of current evidence. We performed a noninterventional retrospective chart review; different characteristics depending on geographical origin were compared. A case-control study was also performed to describe factors potentially associated with chronic or past hepatitis B virus (HBV) infection. We selected a random sample of 436 patients out of the 2989 immigrants attending during the study period (1989-2008). Hepatitis B serology was performed in 74% (322/436): 10.6% had chronic HBV infection (95% CI: 7.4-13.7%), and 46.9% had evidence of past infection (95% CI: 41.7-52.0%). The average age was 31 years, 60% were men, and 70% were sub-Saharan Africans. Chronic infection was related to being men (OR 2.03; 95%CI: 1.29-3.18), younger (OR 0.98; 0.96-0.99) and sub-Saharan African (OR 5.41; 2.71-10.83). Past or current infection was related to male sex (OR 2.80; 1.81-4.30), longer time elapsed until first seen at the unit (OR 0.998; 0.997-1.000), HIV infection (OR 4.99; 1.15-21.60) and being sub-Saharan African (OR 15.46; 8.97-27.18). These associations were not confirmed after adjustment for geographical origin. In 27% and 29.5% of patients, liver biopsy and treatment, respectively, would have been indicated. Prevalence of chronic HBV infection amongst immigrants is high, especially in sub-Saharan Africans. Almost a third could be considered for liver biopsy or antiviral therapy.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 20367791     DOI: 10.1111/j.1365-2893.2010.01306.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  6 in total

1.  Hepatitis B and Schistosoma co-infection in a non-endemic area.

Authors:  J Á Cuenca-Gómez; J Salas-Coronas; A B Lozano-Serrano; J Vázquez-Villegas; M J Soriano-Pérez; M Estévez-Escobar; A Villarejo-Ordóñez; M T Cabezas-Fernández
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-06-07       Impact factor: 3.267

2.  Screening of imported infectious diseases among asymptomatic sub-Saharan African and Latin American immigrants: a public health challenge.

Authors:  Begoña Monge-Maillo; Rogelio López-Vélez; Francesca F Norman; Federico Ferrere-González; Ángela Martínez-Pérez; José Antonio Pérez-Molina
Journal:  Am J Trop Med Hyg       Date:  2015-02-02       Impact factor: 2.345

3.  Serological pattern of Hepatitis B, C, and HIV infections among immigrants in Sicily: epidemiological aspects and implication on public health.

Authors:  Fabio Tramuto; Walter Mazzucco; Carmelo Massimo Maida; Andrea Affronti; Mario Affronti; Giuseppe Montalto; Francesco Vitale
Journal:  J Community Health       Date:  2012-06

4.  The business traveler. A new high-risk traveler profile?

Authors:  J A Pérez-Molina
Journal:  Rev Clin Esp (Barc)       Date:  2015-08-28

Review 5.  Review of infectious diseases in refugees and asylum seekers-current status and going forward.

Authors:  Andreas Halgreen Eiset; Christian Wejse
Journal:  Public Health Rev       Date:  2017-09-08

6.  Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis.

Authors:  Mingjuan Tan; Ajeet S Bhadoria; Fuqiang Cui; Alex Tan; Judith Van Holten; Philippa Easterbrook; Nathan Ford; Qin Han; Ying Lu; Marc Bulterys; Yvan Hutin
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-11-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.